JOLTS Job Openings (Jun) 7.44M vs 7.5M Expected
Paula Green, the Senior Vice President of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), recently sold shares of the company’s common stock. According to a filing with the Securities and Exchange Commission, Green sold 291 shares on March 20, 2025, at a price of $41.676 per share, totaling approximately $12,127. The stock, currently trading at $44.94, has shown significant volatility this year with a 52-week range of $27.41 to $60.90. According to InvestingPro analysis, the company appears overvalued at current levels.
The transaction was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units. This sale was mandated by Twist Bioscience’s equity incentive plans and was not a discretionary trade by Green. Following the transaction, Green holds 130,621 shares of Twist Bioscience, a company with a market capitalization of $2.68 billion. InvestingPro data shows the company maintains strong liquidity with a current ratio of 4.96 and operates with moderate debt levels. Discover more insights and 7 additional ProTips with an InvestingPro subscription.
In other recent news, Twist Bioscience reported financial results for the first quarter of fiscal year 2025 that exceeded analyst expectations and company guidance. The company’s gross margins surpassed previous guidance, leading to an upward revision of its full-year revenue growth forecast to 19-21% year-over-year. Additionally, Twist Bioscience anticipates improved adjusted EBITDA losses and projects gross margins to be around 49% for the full year. Following these results, Scotiabank (TSX:BNS) raised its price target for Twist Bioscience to $62, maintaining a Sector Outperform rating. Similarly, Barclays (LON:BARC) increased its price target to $58, reiterating an Overweight rating due to the company’s momentum in its Express portfolio and Next-Generation Sequencing tools.
In corporate governance developments, Twist Bioscience’s stockholders approved an increase in authorized common stock by 100 million shares and amendments to the company’s equity incentive plan. These changes include an increase of 3.7 million shares reserved for issuance and the removal of the "evergreen" provision. The amendments aim to provide more flexibility in compensating employees. The company also amended its Charter to exculpate certain officers from liability under specific circumstances. These changes reflect Twist Bioscience’s growth strategy and commitment to aligning employee and shareholder interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.